vs
Side-by-side financial comparison of ASHFORD HOSPITALITY TRUST INC (AHT) and ANI PHARMACEUTICALS INC (ANIP). Click either name above to swap in a different company.
ASHFORD HOSPITALITY TRUST INC is the larger business by last-quarter revenue ($259.0M vs $247.1M, roughly 1.0× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -26.8%, a 37.9% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -6.0%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-86.8M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -7.7%).
Ashford Hospitality Trust Inc is a U.S.-headquartered real estate investment trust focused on upper-upscale full-service hotel properties across key U.S. urban, suburban and resort markets. Its portfolio holds assets under top global hospitality brands, serving business and leisure travelers, with a focus on long-term value growth and stable shareholder returns.
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
AHT vs ANIP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $259.0M | $247.1M |
| Net Profit | $-69.3M | $27.5M |
| Gross Margin | — | — |
| Operating Margin | -2.6% | 14.1% |
| Net Margin | -26.8% | 11.1% |
| Revenue YoY | -6.0% | 29.6% |
| Net Profit YoY | 44.2% | 367.5% |
| EPS (diluted) | $-12.85 | $1.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $259.0M | $247.1M | ||
| Q3 25 | $266.1M | $227.8M | ||
| Q2 25 | $302.0M | $211.4M | ||
| Q1 25 | $277.4M | $197.1M | ||
| Q4 24 | $275.5M | $190.6M | ||
| Q3 24 | $276.6M | $148.3M | ||
| Q2 24 | $316.5M | $138.0M | ||
| Q1 24 | $303.9M | $137.4M |
| Q4 25 | $-69.3M | $27.5M | ||
| Q3 25 | $-60.1M | $26.6M | ||
| Q2 25 | $-30.4M | $8.5M | ||
| Q1 25 | $-20.0M | $15.7M | ||
| Q4 24 | $-124.2M | $-10.3M | ||
| Q3 24 | $-57.9M | $-24.2M | ||
| Q2 24 | $50.3M | $-2.3M | ||
| Q1 24 | $71.6M | $18.2M |
| Q4 25 | -2.6% | 14.1% | ||
| Q3 25 | 4.6% | 15.9% | ||
| Q2 25 | 16.3% | 6.6% | ||
| Q1 25 | 22.2% | 13.3% | ||
| Q4 24 | -17.8% | -2.3% | ||
| Q3 24 | 7.3% | -13.8% | ||
| Q2 24 | 42.8% | 3.7% | ||
| Q1 24 | 50.2% | 14.8% |
| Q4 25 | -26.8% | 11.1% | ||
| Q3 25 | -22.6% | 11.7% | ||
| Q2 25 | -10.1% | 4.0% | ||
| Q1 25 | -7.2% | 8.0% | ||
| Q4 24 | -45.1% | -5.4% | ||
| Q3 24 | -20.9% | -16.3% | ||
| Q2 24 | 15.9% | -1.7% | ||
| Q1 24 | 23.5% | 13.2% |
| Q4 25 | $-12.85 | $1.14 | ||
| Q3 25 | $-11.35 | $1.13 | ||
| Q2 25 | $-6.88 | $0.36 | ||
| Q1 25 | $-4.91 | $0.69 | ||
| Q4 24 | $-13.64 | $-0.45 | ||
| Q3 24 | $-12.39 | $-1.27 | ||
| Q2 24 | $2.50 | $-0.14 | ||
| Q1 24 | $5.99 | $0.82 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $66.1M | $285.6M |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $-626.4M | $540.7M |
| Total Assets | $2.8B | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $66.1M | $285.6M | ||
| Q3 25 | $81.9M | $262.6M | ||
| Q2 25 | $100.0M | $217.8M | ||
| Q1 25 | $85.8M | $149.8M | ||
| Q4 24 | $112.9M | $144.9M | ||
| Q3 24 | $119.7M | $145.0M | ||
| Q2 24 | $121.8M | $240.1M | ||
| Q1 24 | $111.1M | $228.6M |
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.6B | — | ||
| Q1 25 | $2.7B | — | ||
| Q4 24 | $2.6B | — | ||
| Q3 24 | $2.7B | — | ||
| Q2 24 | $2.8B | — | ||
| Q1 24 | $2.9B | — |
| Q4 25 | $-626.4M | $540.7M | ||
| Q3 25 | $-548.7M | $505.8M | ||
| Q2 25 | $-485.5M | $436.8M | ||
| Q1 25 | $-446.1M | $418.6M | ||
| Q4 24 | $-419.2M | $403.7M | ||
| Q3 24 | $-288.4M | $405.9M | ||
| Q2 24 | $-225.9M | $455.8M | ||
| Q1 24 | $-276.8M | $452.0M |
| Q4 25 | $2.8B | $1.4B | ||
| Q3 25 | $3.0B | $1.4B | ||
| Q2 25 | $3.1B | $1.3B | ||
| Q1 25 | $3.1B | $1.3B | ||
| Q4 24 | $3.2B | $1.3B | ||
| Q3 24 | $3.3B | $1.3B | ||
| Q2 24 | $3.3B | $920.8M | ||
| Q1 24 | $3.5B | $914.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $30.4M |
| Free Cash FlowOCF − Capex | $-86.8M | $29.1M |
| FCF MarginFCF / Revenue | -33.5% | 11.8% |
| Capex IntensityCapex / Revenue | 27.5% | 0.5% |
| Cash ConversionOCF / Net Profit | — | 1.10× |
| TTM Free Cash FlowTrailing 4 quarters | $-135.5M | $171.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-15.7M | $30.4M | ||
| Q3 25 | $5.5M | $44.1M | ||
| Q2 25 | $16.3M | $75.8M | ||
| Q1 25 | $-25.0M | $35.0M | ||
| Q4 24 | $-23.6M | $15.9M | ||
| Q3 24 | $795.0K | $12.5M | ||
| Q2 24 | $8.0M | $17.4M | ||
| Q1 24 | $-46.5M | $18.3M |
| Q4 25 | $-86.8M | $29.1M | ||
| Q3 25 | $-226.0K | $38.0M | ||
| Q2 25 | $-3.6M | $71.8M | ||
| Q1 25 | $-44.8M | $32.5M | ||
| Q4 24 | $-131.6M | $13.5M | ||
| Q3 24 | $-21.8M | $7.7M | ||
| Q2 24 | $-22.9M | $13.0M | ||
| Q1 24 | $-80.4M | $13.7M |
| Q4 25 | -33.5% | 11.8% | ||
| Q3 25 | -0.1% | 16.7% | ||
| Q2 25 | -1.2% | 34.0% | ||
| Q1 25 | -16.2% | 16.5% | ||
| Q4 24 | -47.8% | 7.1% | ||
| Q3 24 | -7.9% | 5.2% | ||
| Q2 24 | -7.2% | 9.4% | ||
| Q1 24 | -26.5% | 10.0% |
| Q4 25 | 27.5% | 0.5% | ||
| Q3 25 | 2.1% | 2.7% | ||
| Q2 25 | 6.6% | 1.9% | ||
| Q1 25 | 7.2% | 1.3% | ||
| Q4 24 | 39.2% | 1.3% | ||
| Q3 24 | 8.2% | 3.2% | ||
| Q2 24 | 9.8% | 3.2% | ||
| Q1 24 | 11.2% | 3.3% |
| Q4 25 | — | 1.10× | ||
| Q3 25 | — | 1.66× | ||
| Q2 25 | — | 8.87× | ||
| Q1 25 | — | 2.23× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.16× | — | ||
| Q1 24 | -0.65× | 1.00× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AHT
| Occupancy | $190.2M | 73% |
| Food And Beverage | $51.8M | 20% |
| Hotel Other | $16.6M | 6% |
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
